These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 19616226)

  • 21. Prostate cryoablation: prospective analysis comparing high- and low-risk prostate cancer outcomes.
    El Hayek OR; Alfer W; Reggio E; Pompeo AC; Arap S; Lucon AM; Srougi M
    Urol Int; 2008; 81(2):186-90. PubMed ID: 18758217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative risk stratification predicts likelihood of concurrent PSA-free survival, continence, and potency (the trifecta analysis) after radical retropubic prostatectomy.
    Pierorazio PM; Spencer BA; McCann TR; McKiernan JM; Benson MC
    Urology; 2007 Oct; 70(4):717-22. PubMed ID: 17991543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sooner or later? Outcome analysis of 431 prostate cancer patients treated with postoperative or salvage radiotherapy.
    Jereczek-Fossa BA; Zerini D; Vavassori A; Fodor C; Santoro L; Minissale A; Cambria R; Cattani F; Garibaldi C; Serafini F; Matei VD; de Cobelli O; Orecchia R
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):115-25. PubMed ID: 19004572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
    Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
    Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surgery versus implant for early prostate cancer: results from a single institution, 1992-2005.
    Colberg JW; Decker RH; Khan AM; McKeon A; Wilson LD; Peschel RE
    Cancer J; 2007; 13(4):229-32. PubMed ID: 17762756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.
    Zelefsky MJ; Shi W; Yamada Y; Kollmeier MA; Cox B; Park J; Seshan VE
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1350-6. PubMed ID: 19515504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life.
    Hubosky SG; Fabrizio MD; Schellhammer PF; Barone BB; Tepera CM; Given RW
    J Endourol; 2007 Dec; 21(12):1521-31. PubMed ID: 18186694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single photon emission computerized tomography with capromab pendetide plus computerized tomography image set co-registration independently predicts biochemical failure.
    Ellis RJ; Zhou EH; Fu P; Kaminsky DA; Sodee DB; Faulhaber PF; Bodner D; Resnick MI
    J Urol; 2008 May; 179(5):1768-73; discussion 1773-4. PubMed ID: 18343445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer.
    Ganzer R; Rogenhofer S; Walter B; Lunz JC; Schostak M; Wieland WF; Blana A
    Eur Urol; 2008 Mar; 53(3):547-53. PubMed ID: 17662520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b).
    Chin JL; Al-Zahrani AA; Autran-Gomez AM; Williams AK; Bauman G
    J Urol; 2012 Oct; 188(4):1170-5. PubMed ID: 22901586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma.
    Nurani R; Wallner K; Merrick G; Virgin J; Orio P; True LD
    J Urol; 2007 Nov; 178(5):1968-73; discussion 1973. PubMed ID: 17868717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.
    Pisters LL; Leibovici D; Blute M; Zincke H; Sebo TJ; Slezak JM; Izawa J; Ward JF; Scott SM; Madsen L; Spiess PE; Leibovich BC
    J Urol; 2009 Aug; 182(2):517-25; discussion 525-7. PubMed ID: 19524984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary causes of death after permanent prostate brachytherapy.
    Bittner N; Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Brammer SG; Moyad M
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):433-40. PubMed ID: 18448268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Visually directed transrectal high intensity focused ultrasound for the treatment of prostate cancer: a preliminary report on the Italian experience.
    Mearini L; D'Urso L; Collura D; Zucchi A; Costantini E; Formiconi A; Bini V; Muto G; Porena M
    J Urol; 2009 Jan; 181(1):105-11; discussion 111-2. PubMed ID: 19081465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome analysis of prostate cancer patients with pre-treatment PSA greater than 50 ng/ml.
    Wiebe E; Rodrigues G; Lock M; D'Souza D; Stitt L
    Can J Urol; 2008 Jun; 15(3):4078-83. PubMed ID: 18570713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology.
    Polascik TJ; Nosnik I; Mayes JM; Mouraviev V
    Urology; 2007 Jul; 70(1):117-21. PubMed ID: 17656220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response.
    Alexander BM; Chen MH; Carroll P; D'Amico AV
    Urology; 2007 Aug; 70(2):320-3. PubMed ID: 17826497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials.
    Roach M; Weinberg V; Nash M; Sandler HM; McLaughlin PW; Kattan MW
    J Urol; 2006 Dec; 176(6 Pt 2):S16-20. PubMed ID: 17084158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.
    Morris WJ; Keyes M; Palma D; Spadinger I; McKenzie MR; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Berthelet E; Pai H
    Urology; 2009 Apr; 73(4):860-5; discussion 865-7. PubMed ID: 19168203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.